Essential Guide: Registering as a Medicinal-Product Broker in Ireland

Brief and Easy Explanation

The document is the Health Products Regulatory Authority (HPRA)’s Guide to Registration Requirements for Brokers of Medicinal Products in Ireland. It spells out what companies or individuals must do if they act as a broker (i.e., arrange sales or purchases) of medicinal products (for human use) in Ireland under the Directive 2011/62/EU (the Falsified Medicines Directive). HPRA Assets
Here are the key points presented more simply:

• What is “brokering”?
  It means negotiating the sale or purchase of a medicinal product on behalf of someone else — without taking ownership of the product and without physically handling it. HPRA Assets+1
• How is it different from wholesaling?
  Wholesaling may involve taking ownership or handling the product. Brokering does not. HPRA Assets+1
• What must you do if you broker in Ireland?
  1. You must register with HPRA before you start operations. HPRA Assets+1
  2. You must have a quality system in place, follow Good Distribution Practices (GDP) (even though you’re not physically handling product) and keep proper records to ensure traceability. HPRA Assets
  3. You must keep records of each transaction (date, product name, quantity, supplier & consignee details, batch number for certain products) for at least 5 years. HPRA Assets
  4. If you discover a falsified or suspected-falsified medicinal product, you must immediately report it to HPRA (and to the marketing authorisation holder if applicable). HPRA Assets
  5. Maintain a permanent address and contact details in the EU. HPRA Assets
• What about companies that use brokers?
  If a wholesaler uses a broker, the wholesaler must ensure that the broker is registered and meets the GDP-related requirements. HPRA Assets
• How to apply?
  Use the dedicated HPRA application form “Application for registration of broker of finished medicinal products for human use” (available on the HPRA website) and submit before starting brokering. HPRA may inspect your operations. HPRA Assets

Why This Matters (and Why It’s Good Guidance)

• It addresses a specific but important segment of the medicinal product supply chain (brokers) which often operate behind the scenes. Ensuring they’re registered and compliant strengthens supply-chain integrity.
• The guidance aligns with the FMD’s objective to prevent falsified medicines entering the legal supply chain. HPRA Assets
• It clarifies roles and responsibilities not just for brokers themselves, but also for the wholesalers who contract them (so both sides know what to check).
• It promotes transparency and traceability (through records, audits, registration) which is critical for risk-management in pharma supply chains.
• For you (given your experience in regulatory affairs and pharmacovigilance), it’s a useful reference to ensure your clients’ broker partners in Ireland have the required registration and controls in place — especially if you’re advising on EU/UK supply chains.

---

How You (or Your Clients) Can Use This Guide

Given your role in regulatory affairs / pharmacovigilance (for example via Shudarsana Company), here are some practical next steps:

• Identify whether any of your clients engage brokers (rather than wholesalers) in Ireland. If yes, check if those brokers are on the HPRA broker register.
• For brokers: assist them in preparing the registration application, ensuring all sections are completed, and build in readiness for HPRA inspection.
• Review the broker’s quality system and record-keeping practices: Are they maintaining the required five-year records? Do they have emergency/recall plans? Are they reporting suspected falsified products?
• For wholesalers: ensure due-diligence of any brokers used — e.g., inspection of broker’s quality system or engaging third-party verification. HPRA Assets
• Incorporate this guide into your client SOPs, especially in areas covering third-party intermediaries (such as brokers) in supply-chain contracts.
• Monitor for any changes to HPRA or EU broker/wholesaler guidance to keep your compliance-framework up to date.